Zofran® Birth Defect Studies

Zofran Birth Defect Studies

Zofran Birth Defect Studies find Zofran Increases Risk of Heart Septal Defects

Zofran birth defect studies on births in Sweden between 1998 and 2012 have found that prenatal exposure to Zofran (ondansetron) during early pregnancy doubles the risk of cardiac septum defect in the baby. A cardiac septum defect is a hole in the wall (septum) separating the two upper chambers of the heart (atria) or the wall between the two lower chambers (ventricles). The findings were published in the December 2014 issue of Reproductive Toxicology.

Danish Researchers Find Zofran Associated with Two-Fold Increase in Heart Defects

Zofran birth defect studies on all women giving birth in Denmark between 1997 and 2010 have found that women who take Zofran during early pregnancy double their risk of giving birth to a child with septal defects of the heart—holes in the walls between the heart chambers. The findings were presented on August 26, 2013, at the 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management in Montreal, Canada.

Researchers Find Zofran Increases Risk of Clef Palate

Researchers at the Sloan Epidemiology Center at Boston University, supported by a grant from the Centers for Disease Conrol and Prevention, studied nausea and vomiting during pregnancy (NVP) and the medications used to treat it. Taking ondansetron during the first trimester increased the risk of cleft palate alone by nearly two-and-a-half times. The study was published in the January 2012 issue of Birth Defects Research (Part A): Clinical and Molecular Teratology.